Back to search

Peptide record

TPDB42638

L9 Anticancer standard
18 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.
TPDB42638
L9
Anticancer
Cancer-related peptides
AntiCP 2.0 CancerPPD 2.0 Peptipedia SATPdb dbACP iACP-DRLF
standard
No
A 18-aa standard natural anticancer peptide sequence curated from AntiCP 2.0, CancerPPD 2.0, Peptipedia, and other sources, with an available 3D structural model.
Sequence
PAWRKAARWAWRMLKKAA
Physicochemical Analysis
C103H161N33O19S1
NDCEQGHIFSTYV
A
2197.68
12.71
6
0
11
+6
-1.51
-0.722
55.00
Mammalian: >20 hour Yeast: >20 hour E.coli: ?
16500
750.79
0
Residue Composition
number
6
A
3
R
0
N
0
D
0
C
0
E
0
Q
0
G
0
H
0
I
1
L
3
K
1
M
0
F
1
P
0
S
0
T
3
W
0
Y
0
V
Amino Acid Distribution
A: 6 R: 3 N: 0 D: 0 C: 0 E: 0 Q: 0 G: 0 H: 0 I: 0 L: 1 K: 3 M: 1 F: 0 P: 1 S: 0 T: 0 W: 3 Y: 0 V: 0
Chemical Descriptors
18
C103H161N33O19S1
2197.68
12.71
+6
-1.51
-0.722
Free
L
Cyclic
Free
Antimicrobial
Lactoferrin
Evidence Records 3 records
Evidence 1 Activity

Activity

IC50
IC50=35 µM
Anticancer
35 µM

Target

Skin Cancer
Meth A
Skin

Assay & Model

MTT/MTS assay
4-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2002

Other

Source Activity Label Source Definition
Anticancer
CancerPPD 2.0 manually curated experimentally verified anticancer peptide/protein annotation.
Evidence 2 Activity

Activity

IC50
IC50=32 µM
Anticancer
32 µM

Target

Breast Cancer
MT-1
Breast

Assay & Model

MTT/MTS assay
4-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2002
Evidence 3 Activity

Activity

IC50
IC50=52 µM
Anticancer
52 µM

Target

Colon Cancer
HT-29
Colon

Assay & Model

MTT/MTS assay
4-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2002